Showing results (1-10 of 67) with videos related to
Sort By:
Pageof 7
Lung Cancer (Auckland, N.Z.)|October 2, 2019
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to dateFrancesco Facchinetti, Luc FribouletThe European Respiratory Journal|May 2, 2015
Therapeutic management of ALK+ nonsmall cell lung cancer patientsBoris Duchemann, Luc Friboulet, Benjamin BesseClinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2019
The "Guardian of the Genome"-An Old Key to Unlock the ERCC1 IssueLuc Friboulet, Jean-Charles Soria, Ken André OlaussenTranslational Lung Cancer Research|July 23, 2021
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysisGiorgia Guaitoli, Marcello Tiseo, Massimo Di Maio, et al.Nature Reviews. Clinical Oncology|August 16, 2018
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?Gonzalo Recondo, Francesco Facchinetti, Ken A Olaussen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2019
Facts and New Hopes on Selective FGFR Inhibitors in Solid TumorsFrancesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, et al.Cancer Treatment Reviews|May 6, 2018
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wallAlessandro Leonetti, Francesco Facchinetti, Giulio Rossi, et al.BMC Cancer|June 26, 2010
Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cellsLuc Friboulet, Claire Gourzones, Sai Wah Tsao, et al.DNA Repair|February 27, 2018
A novel antibody-based approach to detect the functional ERCC1-202 isoformMei-Shiue Kuo, Julien Adam, Nicolas Dorvault, et al.Cancer Treatment Reviews|March 26, 2017
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibitionFrancesco Facchinetti, Giulio Rossi, Emilio Bria, et al.Pageof 7